Skip to main
AKTS

AKTS Stock Forecast & Price Target

AKTS Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 71%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Aktis Oncology is a biotech company with a strong discovery platform focused on developing targeted treatments for solid tumors and has a partnership with another company. With a projected stock price of $35 and a value of $1.93 billion, the company is rated as OUTPERFORM due to its promising treatments for prostate and lung cancer and its innovative use of yeast display and DOTA. However, there are potential risks to consider, including negative clinical results and delays in regulatory approval.

Bears say

Aktis Oncology is well-positioned to experience significant growth in the next few years with their pipeline of targeted radiopharmaceutical therapies for solid tumors. However, the limited market for their products and strong competition from other biotech companies present major risks and challenges for the company's future success. Additionally, Aktis Oncology's financial position is concerning, with a high burn rate and a market cap that may not be enough to sustain operations until potential revenue in 2025.

AKTS has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 71% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aktis Oncology Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aktis Oncology Inc (AKTS) Forecast

Analysts have given AKTS a Buy based on their latest research and market trends.

According to 7 analysts, AKTS has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aktis Oncology Inc (AKTS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.